FindMyKOL

Hak Choy, MD

Enriched profile

Professor Emeritus, Radiation Oncology · UT Southwestern Medical Center

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 Dallas, TX · South Central · United StatesSpecialtyRadiation OncologyFocusLung Cancer (NSCLC/SCLC)+1
Active KOLFindMyKOL type: EliteLatest publicationSee ScholarshipOnline presenceNone verifiedPayments2021–2025NIH funding2003–2016Why? →

Hak Choy is Professor Emeritus, Radiation Oncology at UT Southwestern Medical Center. OpenAlex indexes 245 publications with 16,853 citations (h-index 61); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Radiation Oncology profiles in the FindMyKOL directory.

Data verified 9 Nov 2026

Overview

Updated 14 Nov 2026

Hak Choy, MD, is Professor Emeritus, Radiation Oncology at UT Southwestern Medical Center. The public record shows 245 publications with 16,853 citations (h-index 61), centered on Lung Cancer (NSCLC/SCLC), Head & Neck Cancer. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 4 companies, 2 NIH-funded awards (2003–2016).

  • Top research focus: Lung Cancer (NSCLC/SCLC)
  • 6 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 4 companies

Generated from the cited public record · current as of 14 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)5 trialsHead & Neck Cancer1 trialBladder / Urothelial CancerBreast CancerColorectal CancerGastroesophageal CancerNeuro-Oncology / GliomaPancreatic CancerProstate CancerKidney Cancer / RCCTuberculosis

Research focus

OpenAlex concept fingerprint
Lung Cancer (NSCLC/SCLC)Head & Neck Cancer

Drugs & molecules

across trials, industry payments and publications
Lynparzageneric · OlaparibClinical trials—Industry payments8Publications—

Works with

trial sponsors and companies reporting payments
Merck Sharp & Dohme LLCClinical trials—Industry payments12Novocure Inc.Clinical trials—Industry payments11Mevion_Medical_Systems_IncClinical trials—Industry payments6Radiation Therapy Oncology GroupClinical trials2Industry payments—Spectrum Pharmaceuticals, IncClinical trials2Industry payments—University of Texas Southwestern Medical CenterClinical trials2Industry payments—Elekta, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
245publications

Publications indexed by OpenAlex. Counts exclude supporting files.

16,853citations

Citations across these publications.

61h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
6clinical trials

Investigator role on registered studies.

View trials ↓
4companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2003–2016

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 9 Nov 2026

Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:

All 6 trial records: search, sort and filter.Explore →

Industry payments

Updated 9 Nov 2026

4 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 9 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

NIH funding

Updated 9 Nov 2026

2 NIH research awards on record, funded 2003–2016 per NIH RePORTER. The latest:

All 9 award records: search, sort and filter.Explore →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
    Article2,015 citations2015
    doi.org ↗
  2. 02
    Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer
    Article1,047 citations2017
    doi.org ↗
  3. 03
    Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial
    Article746 citations2016
    doi.org ↗
  4. 04
    Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer
    Article591 citations2019
    doi.org ↗
  5. 05
    Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial
    Article554 citations2019
    doi.org ↗
All 245 cited works: search, sort and filter.Explore →

Network

Updated 9 Nov 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Robert D Timmerman46Puneeth Iyengar30Walter John Curran23Rebecca Paulus18Ritsuko U Komaki16Wallace Akerley15Debabrata Saha15Kenneth D. Westover15Elizabeth Gore14Yu Shyr14Laurie E. Gaspar13Jeffrey D. Bradley12Benjamin Movsas12Raquibul Hannan12Jeffrey D. Bradley12David R. Gandara12David E. Gerber12David H. Johnson12Randall S. Hughes11Everett E. Vokes11Ramaswamy Govindan11Maria Werner‐Wasik11Corey Jay Langer11Alana L. Christie10Gregory M.M. Videtic10Aaron Michael Laine9George P. Amorino9Chul Woo Ahn9James Brugarolas9Robert Malcolm MacRae9Hongryull Pyo9Steve B Jiang8Chen Hu8Jeff M. Michalski8Kim Js8Joan H. Schiller8Steven E. Schild8Jeffrey A. Bogart8Lawrence Chinsoo Cho8Osama Mohamad7

Online presence

Updated 9 Nov 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    onclive.com/authors/hak-choy-md

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
  • Other

    utsouthwestern.edu/ctplus/stories/2020/hak-choy-profile.html

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →utsouthwestern.edu ↗
  • Other

    utsouthwestern.edu/ctplus/stories/2022/choy-prof-emeritus.html

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →utsouthwestern.edu ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 9 Nov 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Chair

    Lung Committee, Radiation Therapy Oncology Group

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →utsouthwestern.edu ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.